Aprezo

Aprezo (Apremilast) is used for the treatment of various forms of psoriasis (pustular, non-pustular, drug-induced, etc.), arthritis, which arose as a complication of psoriasis, plaque psoriasis of moderate or severe degree, which cannot be treated with other cytostatics (methotrexate, cyclosporitis, etc.).

Treatment with Aprezo (Apremilast) can be prescribed only by a specialist who has sufficient experience in the diagnosis and treatment of psoriasis and psoriatic arthritis. Always follow your doctor`s instructions when using Aprezo (Apremilast) to get the safest and most effective results from treatment. The dosage is prescribed by the doctor individually for each patient. The recommended dose of apremilast is 30 mg orally 2 times a day, morning and evening, with an interval of about 12 hours. An initial dose titration is required.

If the patient skips taking the drug, then the next dose should be taken as soon as possible. If a dose skip is detected immediately before the time of the next dose, then the missed dose is not taken and proceeds to the next dose at the appropriate time. The patient SHOULD NOT takes two doses of the drug at the same time.

The maximum therapeutic effect was observed in the first 24 weeks of treatment.

The use of Aprezo (Apremilast) may cause side effects in some patients including:

• nausea
• vomiting
• diarrhea
• upper respiratory tract infections
• cough
• headache
• decreased appetite
• insomnia
• depression
• rash
• fatigue
• backache
• weight loss

Contact your doctor immediately if you experience any serious or worrying symptoms.

Patients with rare hereditary disorders in the form of galactose intolerance, with congenital lactase deficiency or with malabsorption of glucose-galactose should not take this drug.

Using during pregnancy

Before starting treatment, it is necessary to exclude pregnancy. Women capable of childbearing should use an effective method of contraception during therapy.

Data on the use of Aprezo (Apremilast) in pregnant women are limited. Aprezo (Apremilast) is contraindicated in pregnancy.

Children

Due to insufficient data on the safety and efficacy of the use of this medicinal product in this age group, it is not recommended for children (under 18 years of age).